Spots Global Cancer Trial Database for consolidation therapy
Every month we try and update this database with for consolidation therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC) | NCT00431613 | Non Small Cell ... | Docetaxel Gemcitabine Carboplatin Chemoradiothera... Docetaxel | 19 Years - 75 Years | Hellenic Oncology Research Group | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy | NCT04418648 | Small Cell Lung... | Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma | NCT00416208 | Multiple Myelom... | Bortezomib | 61 Years - 75 Years | Janssen-Cilag G.m.b.H | |
| Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | NCT00522392 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib lenalidomide dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse | NCT00462865 | Breast Cancer | Gemcitabine and... | 18 Years - 80 Years | Brown University | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | NCT00522392 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib lenalidomide dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Frontline Therapy in de Novo Multiple Myeloma Patients Under 65 | NCT01206205 | Multiple Myelom... | Lenalidomide, B... | 18 Years - 65 Years | University Hospital, Toulouse | |
| Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | NCT00479089 | Bladder Cancer | Docetaxel ZD1839 Dexamethasone | - | M.D. Anderson Cancer Center | |
| Velcade (Bortezomib) Consolidation After Transplant | NCT01539083 | Multiple Myelom... | Thalidomide Bortezomib Cyclophosphamid... Dexamethasone Prednisolone | 18 Years - | Janssen Scientific Affairs, LLC | |
| A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma | NCT00416273 | Multiple Myelom... | Bortezomib No intervention | 18 Years - 60 Years | Janssen-Cilag G.m.b.H | |
| Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | NCT00479089 | Bladder Cancer | Docetaxel ZD1839 Dexamethasone | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
